301230 泓博医药
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)1.1521.5893.3739.19424.060
总资产报酬率 ROA (%)0.9041.2192.6987.22716.206
投入资产回报率 ROIC (%)0.9691.3292.9257.84718.619

边际利润分析
销售毛利率 (%)28.38923.86430.87536.87438.688
营业利润率 (%)6.5630.6677.64615.21119.336
息税前利润/营业总收入 (%)6.7640.8307.38813.68720.267
净利润/营业总收入 (%)7.0673.1387.68214.02816.416

收益指标分析
经营活动净收益/利润总额(%)103.654-261.844107.78495.280100.765
价值变动净收益/利润总额(%)16.550237.82216.8900.6912.551
营业外收支净额/利润总额(%)-0.539-2.769-1.8540.105-0.501

偿债能力分析
流动比率 (X)4.3594.4203.8249.2842.154
速动比率 (X)3.8523.8703.5038.7781.791
资产负债率 (%)21.41021.55324.85414.47637.534
带息债务/全部投入资本 (%)3.5433.1393.3692.50510.776
股东权益/带息债务 (%)2,379.3492,675.3802,473.3903,608.381672.302
股东权益/负债合计 (%)367.070363.973302.350590.777166.427
利息保障倍数 (X)28.5794.595-61.885-8.88519.715

营运能力分析
应收账款周转天数 (天)59.21460.88961.59364.13852.308
存货周转天数 (天)50.82356.64959.82258.26570.563